close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Home・Aandelen Lijst・VIRIDIAN THERAPEUTICS INC
Search

VIRIDIAN THERAPEUTICS INC

Gesloten

SectorGezondheidszorg

31.57 0.64

Strong Buy

Prijsupdate 26 nov 2025, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.53

Max

31.9

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

-35M

Verkoop

70M

71M

Winstmarge

-49.028

Werknemers

143

EBITDA

66M

-34M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+25.6% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

902M

3.1B

Vorige openingsprijs

30.93

Vorige sluitingsprijs

31.57

Nieuwssentiment

By Acuity

50%

50%

168 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

12 / 13.14 Steun & Weerstand

VIRIDIAN THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 nov 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

DJ

Lezen

27 nov 2025, 15:32 UTC

Acquisities, Fusies, Overnames

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

DJ

Lezen

27 nov 2025, 23:50 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

DJ

Lezen

27 nov 2025, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

27 nov 2025, 16:05 UTC

Marktinformatie

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

DJ

Lezen

27 nov 2025, 16:04 UTC

Marktinformatie

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

DJ

Lezen

27 nov 2025, 15:54 UTC

Acquisities, Fusies, Overnames

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

DJ

Lezen

27 nov 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: No Certainty Talks Will Result in Transaction

DJ

Lezen

27 nov 2025, 15:43 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

DJ

Lezen

27 nov 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

DJ

Lezen

27 nov 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

DJ

Lezen

27 nov 2025, 15:11 UTC

Marktinformatie

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

DJ

Lezen

27 nov 2025, 14:26 UTC

Marktinformatie

Hermes' Outperformance Gap Could Narrow -- Market Talk

DJ

Lezen

27 nov 2025, 14:11 UTC

Marktinformatie

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

DJ

Lezen

27 nov 2025, 14:11 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

DJ

Lezen

27 nov 2025, 13:35 UTC

Marktinformatie

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

DJ

Lezen

27 nov 2025, 13:33 UTC

Marktinformatie

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

DJ

Lezen

27 nov 2025, 13:22 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

27 nov 2025, 13:22 UTC

Marktinformatie

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

DJ

Lezen

27 nov 2025, 13:17 UTC

Marktinformatie

LVMH Should Be Able to Recover Next Year -- Market Talk

DJ

Lezen

27 nov 2025, 11:13 UTC

Marktinformatie

European Gas Prices Come Under Pressure -- Market Talk

DJ

Lezen

27 nov 2025, 11:07 UTC

Winsten

Genting: Positive About Prospects Over Longer Term

DJ

Lezen

27 nov 2025, 11:06 UTC

Winsten

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

DJ

Lezen

27 nov 2025, 11:04 UTC

Winsten

Genting: International Travel Demand Expected to Remain Resilient

DJ

Lezen

27 nov 2025, 11:04 UTC

Winsten

Genting: Global Growth Expected to Remain Subdued

DJ

Lezen

27 nov 2025, 11:04 UTC

Winsten

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

DJ

Lezen

27 nov 2025, 10:59 UTC

Winsten

Genting Bhd 3Q Net Profit Fell 86% on Year

DJ

Lezen

27 nov 2025, 10:58 UTC

Winsten

Genting Bhd 3Q Rev Rose 14% on Year

DJ

Lezen

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q Net MYR30.3M

DJ

Lezen

27 nov 2025, 10:56 UTC

Winsten

Genting Bhd 3Q EPS MYR0.0079

DJ

Lezen

Peer Vergelijking

Prijswijziging

VIRIDIAN THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

25.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39.84 USD  25.6%

Hoogste 61 USD

Laagste 14.038 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor VIRIDIAN THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

14

Buy

0

Hold

0

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan VIRIDIAN THERAPEUTICS INC - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

12 / 13.14Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Bearish Evidence

All events are bearish.

Lange Termijn

Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

168 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,105.05

↓-0.35%

JNJ

Johnson and Johnson

207.73

↑ +0.45%

ABBV

AbbVie Inc

227.54

↓-1.85%

UNH

UnitedHealth Group Inc

329.68

↑ +1.07%

AZN

AstraZeneca PLC ADR

93.37

↑ +0.12%
help-icon Live chat